159 related articles for article (PubMed ID: 29179431)
21. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.
Wander SA; Levis MJ; Fathi AT
Ther Adv Hematol; 2014 Jun; 5(3):65-77. PubMed ID: 24883179
[TBL] [Abstract][Full Text] [Related]
22. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Cooper TM; Cassar J; Eckroth E; Malvar J; Sposto R; Gaynon P; Chang BH; Gore L; August K; Pollard JA; DuBois SG; Silverman LB; Oesterheld J; Gammon G; Magoon D; Annesley C; Brown PA
Clin Cancer Res; 2016 Aug; 22(16):4014-22. PubMed ID: 26920889
[TBL] [Abstract][Full Text] [Related]
23. Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
Elmeliegy M; Den Haese J; Talati C; Wetzler M; Jusko WJ
Cancer Chemother Pharmacol; 2020 Sep; 86(3):325-337. PubMed ID: 32748108
[TBL] [Abstract][Full Text] [Related]
24. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
Bhullar J; Natarajan K; Shukla S; Mathias TJ; Sadowska M; Ambudkar SV; Baer MR
PLoS One; 2013; 8(8):e71266. PubMed ID: 23967177
[TBL] [Abstract][Full Text] [Related]
25. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
26. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
[TBL] [Abstract][Full Text] [Related]
27. Fms-like tyrosine kinase 3 is a key factor of male fertility.
Kwon WS; Kim YJ; Ryu DY; Kwon KJ; Song WH; Rahman MS; Pang MG
Theriogenology; 2019 Mar; 126():145-152. PubMed ID: 30553232
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
Zorn JA; Wang Q; Fujimura E; Barros T; Kuriyan J
PLoS One; 2015; 10(4):e0121177. PubMed ID: 25837374
[TBL] [Abstract][Full Text] [Related]
29. CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling.
Kim BR; Jung SH; Han AR; Park G; Kim HJ; Yuan B; Battula VL; Andreeff M; Konopleva M; Chung YJ; Cho BS
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629802
[TBL] [Abstract][Full Text] [Related]
30. Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date.
Fletcher L; Joshi SK; Traer E
Cancer Manag Res; 2020; 12():151-163. PubMed ID: 32021432
[TBL] [Abstract][Full Text] [Related]
31. Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance:
Li J; Kumar P; Anreddy N; Zhang YK; Wang YJ; Chen Y; Talele TT; Gupta K; Trombetta LD; Chen ZS
Oncotarget; 2017 Nov; 8(55):93785-93799. PubMed ID: 29212189
[TBL] [Abstract][Full Text] [Related]
32. Insight into the inhibitor discrimination by FLT3 F691L.
Verma S; Singh A; Kumari A; Pandey B; Jamal S; Goyal S; Sinha S; Grover A
Chem Biol Drug Des; 2018 May; 91(5):1056-1064. PubMed ID: 29336115
[TBL] [Abstract][Full Text] [Related]
33. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
Sandmaier BM; Khaled S; Oran B; Gammon G; Trone D; Frankfurt O
Am J Hematol; 2018 Feb; 93(2):222-231. PubMed ID: 29090473
[TBL] [Abstract][Full Text] [Related]
34. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Dennis M; Thomas IF; Ariti C; Upton L; Burnett AK; Gilkes A; Radia R; Hemmaway C; Mehta P; Knapper S; Clark RE; Copland M; Russell N; Hills RK
Blood Adv; 2021 Dec; 5(24):5621-5625. PubMed ID: 34597366
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Altman JK; Foran JM; Pratz KW; Trone D; Cortes JE; Tallman MS
Am J Hematol; 2018 Feb; 93(2):213-221. PubMed ID: 29139135
[TBL] [Abstract][Full Text] [Related]
36. [Effects of Paclitaxel and Quizartinib Alone and in Combination on AML Cell Line MV4-11 and Its STAT5 Signal Pathway].
Bai ZW; Wu MQ; Zhou BW; Shi ZY; Yao YB; Liu ZF; Pang RL; Zhao WH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):671-676. PubMed ID: 35680789
[TBL] [Abstract][Full Text] [Related]
37. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.
Levis M
Future Oncol; 2014; 10(9):1571-9. PubMed ID: 25145428
[TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
Usuki K; Handa H; Choi I; Yamauchi T; Iida H; Hata T; Ohwada S; Okudaira N; Nakamura K; Sakajiri S
Int J Hematol; 2019 Dec; 110(6):654-664. PubMed ID: 31359361
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
[TBL] [Abstract][Full Text] [Related]
40. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
